Back to Directory
Galcanezumab
Performance & EnduranceAnti-CGRP monoclonal antibody for migraine and cluster headache prevention.
Key Benefits
- ✓Prevents migraines
- ✓First approved for cluster headache
- ✓Monthly self-injection
- ✓Reduces migraine frequency
- ✓Well tolerated
Dosing Information
Dosage Range
120-240 mg
Frequency
Monthly
Typical Duration
Ongoing
Detailed Protocol
Administered via subcutaneous injection monthly. Loading dose of 240mg, then 120mg monthly. Can be self-injected. Prescription required.
About Galcanezumab
Galcanezumab (Emgality) is a humanized monoclonal antibody that binds CGRP. FDA-approved for migraine prevention and episodic cluster headache treatment. Monthly subcutaneous injection.
Research Notes
FDA-approved in 2018 for migraine prevention and cluster headache. First CGRP antibody approved for cluster headache. Monthly self-administration. Standard preventive option.
Potential Side Effects
- •Injection site reactions
- •Nasopharyngitis
- •Generally well tolerated
- •Minimal side effects
Always consult with a healthcare professional before starting any peptide therapy.